Who are PF-07104091 monotherapy dose expansion (ovarian)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pf-08052666, mPnC candidate, Pf-08046045, PF-07321332 Dose 5, Talazoparib with enzalutamide, Isauvuconazole group.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pf-07104091-monotherapy-dose-expansion-ovarian.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

PF-07104091 monotherapy dose expansion (ovarian) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PF-07104091 monotherapy dose expansion (ovarian) (pf-07104091-monotherapy-dose-expansion-ovarian) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: small molecule. Area: Oncology.

marketed small molecule [insert molecular target] Oncology Live · refreshed every 30 min

Target snapshot

PF-07104091 monotherapy dose expansion (ovarian) (pf-07104091-monotherapy-dose-expansion-ovarian) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PF-07104091 monotherapy dose expansion (ovarian) TARGET	pf-07104091-monotherapy-dose-expansion-ovarian	Pfizer	marketed	small molecule	[insert molecular target]
Pf-08052666	pf-08052666	Pfizer	marketed	Small molecule inhibitor	Specific protein involved in disease pathways	Unknown
mPnC candidate	mpnc-candidate	Pfizer	marketed	Novel therapeutic agent	Specific protein or receptor involved in disease pathology	TBD
Pf-08046045	pf-08046045	Pfizer	marketed	Small molecule inhibitor	Specific protein involved in cancer cell proliferation	TBD
PF-07321332 Dose 5	pf-07321332-dose-5	Pfizer	marketed	Protease inhibitor	Main protease (MPro) of SARS-CoV-2	Pending regulatory approval
Talazoparib with enzalutamide	talazoparib-with-enzalutamide	Pfizer	marketed	PARP inhibitor and androgen receptor inhibitor	PARP enzymes and androgen receptor	Not yet launched
Isauvuconazole group	isauvuconazole-group	Pfizer	marketed	Echinocandin	β-(1,3)-D-glucan synthase	Not yet launched

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (small molecule class)

Pfizer · 5 drugs in this class
Qilu Pharmaceutical Co., Ltd. · 4 drugs in this class
Jiangsu HengRui Medicine Co., Ltd. · 3 drugs in this class
Avalo Therapeutics, Inc. · 1 drug in this class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 drug in this class
Cipla BioTec Pvt. Ltd. · 1 drug in this class
ChemRar Research and Development Institute, LLC · 1 drug in this class
Daewoong Pharmaceutical Co. LTD. · 1 drug in this class
Dilafor AB · 1 drug in this class
Daewon Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PF-07104091 monotherapy dose expansion (ovarian) — Competitive Intelligence Brief. https://druglandscape.com/ci/pf-07104091-monotherapy-dose-expansion-ovarian. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab